PR93526

BEIJING, China, Dec. 7, 2021 /PRNewswire=KYODO JBN/ --

Sino Biological, Inc. (http://www.sinobiological.com; SHE: 301047) announced

today that it has launched a panel of research reagents for the newly

identified Omicron variant (B.1.1.529) of the SARS-COV-2 virus, which quickly

raised concerns around the world because of the high number of mutations it

carries, especially the 30-plus mutations on the Spike protein.

Sino Biological's new Omicron product line includes recombinant Omicron Spike

proteins

(RBD(https://www.sinobiological.com/recombinant-proteins/sars-cov-2-cov-spike-40

592-v08h121),

S1(https://www.sinobiological.com/recombinant-proteins/sars-cov-2-cov-spike-4059

1-v08h41), and S-ECD

trimer(https://www.sinobiological.com/recombinant-proteins/sars-cov-2-cov-spike-

40589-v08h26)), monoclonal

antibodies(https://www.sinobiological.com/antibodies/cov-spike-40592-mm117)

recognizing the Omicron Spike protein, and the Omicron pseudovirus assay CRO

service. These reagents are critical and urgently needed research tools for

scientists and researchers worldwide to understand the impact of the new

Omicron mutations on viral transmission as well as therapeutic neutralizing

antibody and prophylactic vaccine effectiveness.

"Sino Biological produced the key spike protein reagents within a record

11-days in Jan 2020and supported thousands of scientists and researchers in

over 70countries worldwide for their COVID-19 research which led to close to

1000publications to date" Sino Biological CEO Dr. Jie Zhang stated, "With the

state-of-the-art platform technology and expertise accumulated over a decade,

in a race against time and the pandemic, we are very pleased to be able to

produce the Omicron RBD protein in a new record of 6days, spike binding

antibody in 8days, the spike-S1, S-ECD trimer proteins and pseudovirus in

10days. We'll continue to monitor new mutations, and make sure we make research

tools available to scientists as quickly as we possibly can."

Sino Biological produces a comprehensive list of research reagents to support

the global fight against the COVID-19 pandemic with over 400protein and

antibody reagent

products(https://www.sinobiological.com/research/virus/2019-ncov-antigen). Sino

Biological's protein and antibody products have also been used to manufacture

COVID diagnostic tests.

About Sino Biological

Sino Biological is an international biological reagent supplier and service

provider. The company specializes in recombinant antigen production and

antibody development. The company's ever-growing portfolio of products includes

over 6000 recombinant proteins, 13,000 antibodies, ELISA assay kits, expression

clones, cell culture media, and other molecular biology tools. The company also

offers a variety of customized services, mainly focusing on recombinant

production of antigens and antibodies. Sino Biological is dedicated to virology

and infectious disease research. Its newly launched ProVir(TM)

collection(https://www.sinobiological.com/research/virus) is the world's

largest viral antigen bank, carrying over 1000 viral products from 350 strains

of viruses.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the

meaning of the Private Securities Litigation Reform Act. These statements are

based on management's current expectations and are subject to uncertainty and

changes in circumstances. Actual results may differ materially from those

included in these statements due to a variety of factors, over which Biological

has no control. Sino Biological assumes no obligation to update these

forward-looking statements and do not intend to do so. More information about

these factors is contained in Sino Biological's filings with the Shenzhen Stock

Exchange.

SOURCE: Sino Biological, Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=410048

   Caption: Sino Biological newly launched a panel of research reagents for SARS-CoV-2

Omicron variant (B.1.1.529)， including includes recombinant Omicron Spike

proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognizing the

Omicron Spike protein, and the Omicron pseudovirus assay CRO service.